 Xiao-Jing Wang
Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 7 | 2012 | 643 | 0.820 |
Why?
| | Psoriasis | 3 | 2012 | 113 | 0.790 |
Why?
| | Transforming Growth Factor beta | 4 | 2012 | 475 | 0.670 |
Why?
| | Receptors, Transforming Growth Factor beta | 3 | 2012 | 55 | 0.650 |
Why?
| | Smad4 Protein | 2 | 2012 | 33 | 0.630 |
Why?
| | Epidermis | 3 | 2011 | 157 | 0.630 |
Why?
| | Smad7 Protein | 2 | 2011 | 20 | 0.590 |
Why?
| | Hair Follicle | 2 | 2008 | 48 | 0.520 |
Why?
| | Keratinocytes | 6 | 2011 | 250 | 0.510 |
Why?
| | Mice, Transgenic | 9 | 2012 | 2184 | 0.450 |
Why?
| | Transforming Growth Factor beta1 | 3 | 2012 | 176 | 0.420 |
Why?
| | Transgenes | 2 | 2011 | 191 | 0.400 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2012 | 1437 | 0.350 |
Why?
| | Smad2 Protein | 2 | 2008 | 36 | 0.340 |
Why?
| | Mouth Neoplasms | 2 | 2011 | 90 | 0.310 |
Why?
| | Genetic Techniques | 1 | 2010 | 67 | 0.300 |
Why?
| | Head and Neck Neoplasms | 2 | 2012 | 562 | 0.300 |
Why?
| | Promoter Regions, Genetic | 4 | 2011 | 1246 | 0.300 |
Why?
| | Skin Neoplasms | 2 | 2008 | 850 | 0.300 |
Why?
| | Keratins | 1 | 2010 | 171 | 0.290 |
Why?
| | Skin | 3 | 2009 | 762 | 0.290 |
Why?
| | Wound Healing | 1 | 2011 | 352 | 0.280 |
Why?
| | Desmogleins | 1 | 2008 | 3 | 0.280 |
Why?
| | Alopecia | 1 | 2008 | 37 | 0.280 |
Why?
| | Transcriptional Activation | 2 | 2008 | 372 | 0.270 |
Why?
| | Mice | 12 | 2012 | 18261 | 0.260 |
Why?
| | Respiratory Mucosa | 1 | 2010 | 322 | 0.250 |
Why?
| | Signal Transduction | 6 | 2012 | 5185 | 0.240 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2006 | 254 | 0.220 |
Why?
| | Adenocarcinoma | 1 | 2012 | 923 | 0.210 |
Why?
| | beta Catenin | 1 | 2006 | 252 | 0.210 |
Why?
| | Down-Regulation | 4 | 2011 | 616 | 0.200 |
Why?
| | Pancreatic Neoplasms | 1 | 2012 | 926 | 0.200 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1186 | 0.190 |
Why?
| | Animals | 12 | 2012 | 37948 | 0.180 |
Why?
| | Stem Cells | 1 | 2006 | 621 | 0.180 |
Why?
| | BRCA1 Protein | 2 | 2011 | 82 | 0.160 |
Why?
| | Alcohol Oxidoreductases | 2 | 2011 | 62 | 0.160 |
Why?
| | Lung Neoplasms | 1 | 2012 | 2660 | 0.140 |
Why?
| | RNA, Small Interfering | 2 | 2012 | 631 | 0.130 |
Why?
| | DNA-Binding Proteins | 3 | 2011 | 1484 | 0.130 |
Why?
| | Cell Movement | 2 | 2012 | 959 | 0.130 |
Why?
| | Mesoderm | 2 | 2008 | 146 | 0.120 |
Why?
| | Cell Proliferation | 3 | 2011 | 2489 | 0.120 |
Why?
| | Epithelium | 2 | 2008 | 310 | 0.120 |
Why?
| | Gene Deletion | 2 | 2008 | 392 | 0.120 |
Why?
| | Transcription, Genetic | 2 | 2011 | 1468 | 0.100 |
Why?
| | Inflammation | 3 | 2011 | 2870 | 0.090 |
Why?
| | Disease Progression | 2 | 2012 | 2847 | 0.090 |
Why?
| | Fanconi Anemia | 1 | 2012 | 11 | 0.090 |
Why?
| | Intestinal Polyposis | 1 | 2012 | 7 | 0.090 |
Why?
| | Laryngeal Neoplasms | 1 | 2011 | 36 | 0.090 |
Why?
| | Models, Immunological | 1 | 2012 | 100 | 0.090 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2012 | 47 | 0.090 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2011 | 55 | 0.080 |
Why?
| | Models, Biological | 2 | 2012 | 1811 | 0.080 |
Why?
| | Mice, Knockout | 2 | 2008 | 3109 | 0.080 |
Why?
| | Th17 Cells | 1 | 2012 | 100 | 0.080 |
Why?
| | Collagen Type I | 1 | 2011 | 143 | 0.080 |
Why?
| | Cells, Cultured | 2 | 2008 | 4110 | 0.080 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 174 | 0.080 |
Why?
| | Cholangiocarcinoma | 1 | 2012 | 108 | 0.080 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 503 | 0.080 |
Why?
| | Acetone | 1 | 2010 | 11 | 0.080 |
Why?
| | RNA Interference | 1 | 2012 | 473 | 0.080 |
Why?
| | Neovascularization, Physiologic | 1 | 2011 | 191 | 0.080 |
Why?
| | NAD | 1 | 2010 | 82 | 0.080 |
Why?
| | Mifepristone | 1 | 2010 | 53 | 0.080 |
Why?
| | Oils | 1 | 2010 | 22 | 0.080 |
Why?
| | Humans | 13 | 2012 | 144667 | 0.080 |
Why?
| | Enzyme Activation | 1 | 2011 | 762 | 0.080 |
Why?
| | Bronchoalveolar Lavage | 1 | 2010 | 88 | 0.080 |
Why?
| | Cadherins | 1 | 2011 | 200 | 0.080 |
Why?
| | Skin Physiological Phenomena | 1 | 2009 | 24 | 0.080 |
Why?
| | Gene Expression | 2 | 2005 | 1476 | 0.080 |
Why?
| | Cell Line, Tumor | 3 | 2012 | 3523 | 0.080 |
Why?
| | Colonic Neoplasms | 1 | 2012 | 256 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2008 | 2037 | 0.070 |
Why?
| | Hormones | 1 | 2010 | 133 | 0.070 |
Why?
| | Integrases | 1 | 2010 | 122 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 550 | 0.070 |
Why?
| | Fluorescent Antibody Technique, Direct | 1 | 2008 | 9 | 0.070 |
Why?
| | Smad5 Protein | 1 | 2008 | 7 | 0.070 |
Why?
| | Smad1 Protein | 1 | 2008 | 17 | 0.070 |
Why?
| | Thiazolidinediones | 1 | 2009 | 139 | 0.070 |
Why?
| | Receptors, Progesterone | 1 | 2010 | 243 | 0.070 |
Why?
| | Immune System | 1 | 2009 | 178 | 0.070 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2008 | 93 | 0.070 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1046 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2012 | 1766 | 0.070 |
Why?
| | Lymphocyte Activation | 1 | 2012 | 1124 | 0.070 |
Why?
| | Trachea | 1 | 2010 | 258 | 0.070 |
Why?
| | NF-kappa B | 1 | 2011 | 657 | 0.070 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2008 | 142 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 667 | 0.060 |
Why?
| | Sebaceous Glands | 1 | 2006 | 5 | 0.060 |
Why?
| | Ligands | 1 | 2008 | 662 | 0.060 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 300 | 0.060 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1705 | 0.060 |
Why?
| | Wnt Proteins | 1 | 2006 | 133 | 0.060 |
Why?
| | Morphogenesis | 1 | 2006 | 172 | 0.060 |
Why?
| | MicroRNAs | 1 | 2011 | 689 | 0.060 |
Why?
| | Carcinoma in Situ | 1 | 2005 | 44 | 0.060 |
Why?
| | Mice, Inbred ICR | 1 | 2005 | 113 | 0.060 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2006 | 191 | 0.050 |
Why?
| | Biomarkers, Tumor | 1 | 2011 | 1319 | 0.050 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 978 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2006 | 284 | 0.050 |
Why?
| | Basement Membrane | 1 | 2004 | 31 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2012 | 2815 | 0.050 |
Why?
| | Trans-Activators | 1 | 2005 | 397 | 0.050 |
Why?
| | Macrophages | 1 | 2010 | 1496 | 0.040 |
Why?
| | Time Factors | 1 | 2011 | 7140 | 0.040 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 5967 | 0.040 |
Why?
| | Female | 4 | 2012 | 78304 | 0.030 |
Why?
| | Breast Neoplasms | 1 | 2011 | 2365 | 0.030 |
Why?
| | Male | 3 | 2012 | 72431 | 0.030 |
Why?
| | Lung | 1 | 2010 | 4089 | 0.030 |
Why?
| | Cytokines | 1 | 2004 | 2045 | 0.030 |
Why?
| | Phenotype | 1 | 2004 | 3147 | 0.030 |
Why?
| | Mutation | 1 | 2006 | 4081 | 0.030 |
Why?
| | E2F4 Transcription Factor | 1 | 2010 | 6 | 0.020 |
Why?
| | Cyclic N-Oxides | 1 | 2010 | 32 | 0.020 |
Why?
| | Spin Labels | 1 | 2010 | 59 | 0.020 |
Why?
| | Gene Silencing | 1 | 2011 | 202 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2008 | 17149 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1047 | 0.020 |
Why?
| | DNA Repair | 1 | 2010 | 256 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1307 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1995 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2010 | 1078 | 0.020 |
Why?
| | DNA Methylation | 1 | 2011 | 664 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2011 | 3603 | 0.010 |
Why?
|
|
Wang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|